Other languages Genexine, Inc.

Equities

A095700

KR7095700001

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-04-25 EDT			5-day change	1st Jan Change
7,280 ^KRW	-0.95%		+3.41%	-26.46%

2023	Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	23-10-23
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	23-08-31
Sector Update: Health Care	23-08-31
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	23-08-31
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	23-08-31
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study	23-08-30
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer	23-01-20
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference	23-01-08
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer	22-09-07
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022	22-08-25
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	22-08-17
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency	22-06-14
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)	22-06-14
Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer	22-06-07
Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation	22-05-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Genexine, Inc.

Equities

A095700

KR7095700001

Other languages

Filters